Study of IBI363 in Patients with Advanced First-line Gastric Cancer
NCT06610799
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
40
Enrollment
OTHER
Sponsor class
Conditions
IBI363 + Chemotherapy
Interventions
DRUG:
IBI363
Sponsor
Xiangdong Cheng